TYK2 in Tumor Immunosurveillance

被引:21
|
作者
Karjalainen, Anzhelika [1 ]
Shoebridge, Stephen [1 ]
Krunic, Milica [1 ]
Simonovic, Natalija [1 ,2 ]
Tebb, Graham [1 ]
Macho-Maschler, Sabine [1 ]
Strobl, Birgit [1 ]
Mueller, Mathias [1 ]
机构
[1] Univ Vet Med Vienna, Inst Anim Breeding & Genet, A-1210 Vienna, Austria
[2] Med Univ Vienna, Ctr Anat & Cell Biol, A-1090 Vienna, Austria
基金
奥地利科学基金会;
关键词
tyrosine kinase 2; Janus kinase (JAK) family; STATs; immunoediting; cancer-immunity cycle; interferons; interleukins; TYROSINE KINASE 2; TARGET-GENE-EXPRESSION; IFN-GAMMA PRODUCTION; REGULATORY T-CELLS; JAK-STAT PATHWAY; CYTOKINE RECEPTOR; IMMUNE SURVEILLANCE; I INTERFERONS; SIGNALING PATHWAYS; CANCER IMMUNOSURVEILLANCE;
D O I
10.3390/cancers12010150
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We review the history of the tyrosine kinase 2 (TYK2) as the founding member of the Janus kinase (JAK) family and outline its structure-function relation. Gene-targeted mice and hereditary defects of TYK2 in men have established the biological and pathological functions of TYK2 in innate and adaptive immune responses to infection and cancer and in (auto-)inflammation. We describe the architecture of the main cytokine receptor families associated with TYK2, which activate signal transducers and activators of transcription (STATs). We summarize the cytokine receptor activities with well characterized dependency on TYK2, the types of cells that respond to cytokines and TYK2 signaling-induced cytokine production. TYK2 may drive beneficial or detrimental activities, which we explain based on the concepts of tumor immunoediting and the cancer-immunity cycle in the tumor microenvironment. Finally, we summarize current knowledge of TYK2 functions in mouse models of tumor surveillance. The biology and biochemistry of JAKs, TYK2-dependent cytokines and cytokine signaling in tumor surveillance are well covered in recent reviews and the oncogenic properties of TYK2 are reviewed in the recent Special Issue 'Targeting STAT3 and STAT5 in Cancer' of Cancers.
引用
收藏
页数:24
相关论文
共 50 条
  • [1] In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity
    Prchal-Murphy, Michaela
    Witalisz-Siepracka, Agnieszka
    Bednarik, Karoline T.
    Putz, Eva Maria
    Gotthardt, Dagmar
    Meissl, Katrin
    Sexl, Veronika
    Mueller, Mathias
    Strobl, Birgit
    ONCOIMMUNOLOGY, 2015, 4 (11):
  • [2] Tyk2 is a tumor suppressor in colorectal cancer
    Moritsch, Stefan
    Moedl, Bernadette
    Scharf, Irene
    Janker, Lukas
    Zwolanek, Daniela
    Timelthaler, Gerald
    Casanova, Emilio
    Sibilia, Maria
    Mohr, Thomas
    Kenner, Lukas
    Herndler-Brandstetter, Dietmar
    Gerner, Christopher
    Mueller, Mathias
    Strobl, Birgit
    Eferl, Robert
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [3] Central TYK2 Inhibition Identifies TYK2 as a Key Neuroimmune Modulator
    Molitor, Tyler
    Hayashi, Genki
    Lin, Mei-Yao
    Dunn, Carissa
    Peterson, Nathan
    Poston, Robert
    Kurnellas, Michael
    Traver, David
    Patel, Seona
    Akgungor, Zeynep
    Leonardi, Virginia
    Lewis, Colizel
    Segales, Joshua
    Wood, Steve
    Rassoulpour, Arash
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 611 - 611
  • [4] Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors
    Du, Si-Shi
    Fang, Yu-Qing
    Zhang, Wen
    Rao, Guo-Wu
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (20) : 2900 - 2920
  • [5] Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance
    Vielnascher, Raimund M.
    Hainzl, Eva
    Leitner, Nicole R.
    Rammerstorfer, Michael
    Popp, David
    Witalisz, Agnieszka
    Rom, Rita
    Karaghiosoff, Marina
    Kolbe, Thomas
    Mueller, Simone
    Ruelicke, Thomas
    Lassnig, Caroline
    Strobl, Birgit
    Mueller, Mathias
    TRANSGENIC RESEARCH, 2014, 23 (03) : 519 - 529
  • [6] Discovery of a Potent and Subtype-Selective Tyk2 Degrader Based on an Allosteric Tyk2 Inhibitor
    Kato, Jun-Ya
    Korenaga, Shigeru
    Iwakura, Masaru
    SSRN, 2022,
  • [7] Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
    Liu, Chunjian
    Lin, James
    Langevine, Charles
    Smith, Daniel
    Li, Jianqing
    Tokarski, John S.
    Khan, Javed
    Ruzanov, Max
    Strnad, Joann
    Zupa-Fernandez, Adriana
    Cheng, Lihong
    Gillooly, Kathleen M.
    Shuster, David
    Zhang, Yifan
    Thankappan, Anil
    McIntyre, Kim W.
    Chaudhry, Charu
    Elzinga, Paul A.
    Chiney, Manoj
    Chimalakonda, Anjaneya
    Lombardo, Louis J.
    Macor, John E.
    Carter, Percy H.
    Burke, James R.
    Weinstein, David S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (01) : 677 - 694
  • [8] The role of Tyk2 in adaptive immunity
    Simma, O
    Sexl, V
    Stoiber, D
    PHARMACOLOGY, 2005, 75 (04) : 199 - 199
  • [9] Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor
    Kato, Jun-ya
    Korenaga, Shigeru
    Iwakura, Masaru
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 79
  • [10] Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance
    Raimund M. Vielnascher
    Eva Hainzl
    Nicole R. Leitner
    Michael Rammerstorfer
    David Popp
    Agnieszka Witalisz
    Rita Rom
    Marina Karaghiosoff
    Thomas Kolbe
    Simone Müller
    Thomas Rülicke
    Caroline Lassnig
    Birgit Strobl
    Mathias Müller
    Transgenic Research, 2014, 23 : 519 - 529